Advances in Regulatory Risk

Jorge discusses the incredible advances in regulatory risk, highlighting the increasing number of FDA approvals for generics and cell therapies. He emphasizes that as therapies become more powerful and effective, the perceived regulatory risk diminishes. Gene therapy and Car T, once considered risky, have shown such effectiveness that they received unanimous FDA panel recommendations.